Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.
about
Targeted Delivery Systems for Molecular Therapy in Skeletal DisordersBiosafe nanoscale pharmaceutical adjuvant materialsEnzyme-responsive nanomaterials for controlled drug deliveryToward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesHuman serum albumin and p53-activating peptide fusion protein is able to promote apoptosis and deliver fatty acid-modified moleculesDetection of Peptide-based nanoparticles in blood plasma by ELISAVirocidal activity of Egyptian scorpion venoms against hepatitis C virus.Noninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs).A novel microtubule de-stabilizing complementarity-determining region C36L1 peptide displays antitumor activity against melanoma in vitro and in vivoPhysicochemical properties and in vitro cytotoxicity of iron oxide-based nanoparticles modified with antiangiogenic and antitumor peptide A7R.Self-assembled micelles of amphiphilic poly(L-phenylalanine)-b-poly(L-serine) polypeptides for tumor-targeted delivery.Peptide internalization enabled by folding: triple helical cell-penetrating peptides.Intracellular GSH-activated galactoside photosensitizers for targeted photodynamic therapy and chemotherapy.Cancer treatment using peptides: current therapies and future prospectsTransformable Peptide Nanocarriers for Expeditious Drug Release and Effective Cancer Therapy via Cancer-Associated Fibroblast Activation.VIP-targeted Cytotoxic Nanomedicine for Breast CancerScavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles.Effects of redox state on the efficient uptake of cell permeable Peptide in Mammalian cells.Nanotherapeutics in the EU: an overview on current state and future directions.Designing protein-based biomaterials for medical applications.Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides.Applications of cell-penetrating peptides for tumor targeting and future cancer therapies.Interfacing materials science and biology for drug carrier design.Smart linkers in polymer-drug conjugates for tumor-targeted delivery.Strategies to release doxorubicin from doxorubicin delivery vehicles.A General Strategy for Facile Synthesis and In Situ Screening of Self-Assembled Polymer-Peptide Nanomaterials.Enzyme-triggered delivery of chlorambucil from conjugates based on the cell-penetrating peptide BP16.Cathepsin-B induced controlled release from peptide-capped mesoporous silica nanoparticles.Tackling breast cancer chemoresistance with nano-formulated siRNA.Peptides as a therapeutic avenue for nanocarrier-aided targeting of glioma.Enzyme-responsive intracellular-controlled release using silica mesoporous nanoparticles capped with ε-poly-L-lysine.Delivery of nucleic acids for cancer gene therapy: overcoming extra- and intra-cellular barriers.Evaluation of Cell Penetrating Peptide Delivery System on HPV16E7 Expression in Three Types of Cell LineEngineering an Affinity-Enhanced Peptide through Optimization of Cyclization Chemistry.A Facile Cyclization Method Improves Peptide Serum Stability and Confers Intrinsic Fluorescence.Stimulus-Responsive Short Peptide Nanogels for Controlled Intracellular Drug Release and for Overcoming Tumor Resistance.Cytotoxicity Study of Cyclopentapeptide Analogues of Marine Natural Product Galaxamide towards Human Breast Cancer Cells.Responsive Hybrid (Poly)peptide-Polymer Conjugates.Peptide-mediated vectorization of metal complexes: conjugation strategies and biomedical applications.Polymeric micelles for targeted tumor therapy of platinum anticancer drugs.
P2860
Q26752158-CD6E3AEF-D94F-4400-AA65-9E4E664834D8Q26829798-38E762B1-D1D9-42DB-AC1B-CD66A391E481Q26992127-FE5DA6BF-C75C-4D27-8EC0-B9A9892A4F30Q26995399-352E3971-CA30-4F31-9C12-660F2F388259Q28535347-C96B69A0-AF5D-47A3-94FE-25A855B50D73Q28547412-5D131770-AD2D-44BB-B6CE-8472F7DF26D3Q30389258-1CC53111-ECDC-45A4-BCA7-4D8F4D2EDD15Q30540289-8979002A-5751-4DEF-950A-EC8DED49A34FQ30665888-2AFB2EC0-5D76-4CBB-99FD-E5835B8B1E2BQ30847079-4E451991-5ECD-4005-AB70-09776F33D2C0Q34731653-04F663CD-80C3-40D4-9686-5BE9DECEA922Q35601619-8693E7FE-8DF7-4564-AEC1-E0CD27120AE1Q36220307-31D83FF4-4C9B-4A59-8452-06B2DC1AFD85Q36515785-C3ACC481-E9F6-4B77-97A1-09BF8A06BB65Q36531166-F341E4A6-5370-4A98-B351-000D20C4B476Q36538910-14E722E7-FB75-4838-AD5C-5F5A7742EF3BQ36997612-7CC18E7B-185C-492E-8F5B-F68556D7232BQ37065310-5052D7EF-B5D7-4F78-8FCC-C0ACCA7B78D4Q37601242-E2FB1CFA-6B4D-432A-B03D-20FAEE113B60Q38152205-371A2DF8-6F39-45AC-BA66-06196CF69A4BQ38160482-DDBE6DF8-8955-490C-86DA-CE624577D706Q38166533-D7CBF6ED-1350-4433-AB56-EBD288B04320Q38366527-BEC6DFF6-D2F7-49E1-8DD5-58882522A766Q38631193-60195106-65BA-4BB5-B5F7-62FEED16BE71Q38643071-D04F87C1-3901-4E78-8119-873EF7EF4264Q38809537-62566095-32FA-49EF-BFDD-2E822ECDA93DQ38932275-8ED4BA1A-2B96-494E-828C-CB2DB5AC0A24Q38949120-595A005E-A4A8-4178-9E17-1896749082F9Q38959517-A85874E3-0223-4708-981D-3026DE16D202Q38969029-3D254F5F-6DF4-4998-B3A1-ECA68A240015Q39007918-8931B84C-1B51-411E-9F21-084E747F1826Q40599238-51326CE4-26A2-40BA-A4E5-C473A56F8357Q41674446-2FC2FDA0-7289-45B8-8674-3439E6E67D7BQ47110304-1AFFF86F-CE7D-4590-870B-378EE3CEA460Q47433262-575964E0-B960-41AF-863D-EEFC476BB34FQ48016094-F7B98B0D-1D9D-42A1-A95E-DD70CE5077CFQ48095070-D1DDCF41-79EF-4B02-BDBB-886DB454C965Q50073312-4CB7CCC3-4934-411D-BB8E-D41BF0FFFF97Q50860069-E192AB68-B384-46EB-9FF4-37B301FCB60AQ50960383-5A40D657-1004-401F-9518-524438BD26ED
P2860
Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Peptides in cancer nanomedicin ...... gands and protease substrates.
@ast
Peptides in cancer nanomedicin ...... gands and protease substrates.
@en
type
label
Peptides in cancer nanomedicin ...... gands and protease substrates.
@ast
Peptides in cancer nanomedicin ...... gands and protease substrates.
@en
prefLabel
Peptides in cancer nanomedicin ...... gands and protease substrates.
@ast
Peptides in cancer nanomedicin ...... gands and protease substrates.
@en
P2860
P1476
Peptides in cancer nanomedicin ...... gands and protease substrates.
@en
P2093
Henry S Eden
Xiao-Xiang Zhang
P2860
P356
10.1016/J.JCONREL.2011.10.023
P407
P577
2011-10-26T00:00:00Z